PT-141 FDA-Approved Libido
Bremelanotide — the FDA-approved melanocortin agonist (Vyleesi) for hypoactive sexual desire disorder.
Book Free ConsultationCall 310.299.4444What PT-141 actually is
Bremelanotide (PT-141) is a melanocortin receptor agonist FDA-approved in 2019 as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.1 Unlike PDE-5 inhibitors (which act peripherally on vascular smooth muscle), PT-141 acts centrally through MC4R in the hypothalamus.
The mechanism is meaningful: PT-141 affects desire — not just vasodilation. This makes it useful in patients whose sexual concerns are about motivation and arousal rather than mechanics. It’s commonly prescribed off-label for men as well, with similar central mechanism.2
At Luxbae, PT-141 is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.
Mechanism — Central MC4R agonism
Activates MC4R in hypothalamic regions implicated in sexual motivation and arousal — central rather than peripheral mechanism.2
What the research shows
FDA-approved. Vyleesi approval for HSDD establishes regulatory and safety baseline.1
Central libido effect. Affects desire and arousal rather than vascular mechanics.
Effective in PDE-5 non-responders. Useful when sildenafil/tadalafil fail or are contraindicated.
Side effects: Nausea (most common; typically improves with subsequent doses), facial flushing, headache, transient BP elevation.
FDA note: Bremelanotide is FDA-approved as Vyleesi for HSDD in premenopausal women. Off-label use in men and other contexts is at physician discretion.
PT-141 FAQ
How is this different from sildenafil?
Central mechanism (desire) rather than peripheral (vasodilation). Different complaints, different tools.
Will it work for me?
Best for desire-related concerns; less effective when issue is purely mechanical.
References
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):899-908.
- Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007.
- Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004.